Research
Hormonal
Adipokines such as resistin and leptin play a role in insulin resistance, with resistin exhibiting insulin-antagonistic effects and leptin signaling influencing adiponectin expression.
Managing body weight can help normalize adipokine levels, potentially improving insulin sensitivity by reducing resistin and restoring healthy leptin-adiponectin balance.
ModerateSupportsMEDIUM confidence
Resistin induces insulin resistance through inhibition of glucose transport in vitro and increases hepatic glucose production and fasting blood glucose concentrations in vivo... Impaired leptin signaling may contribute to low adiponectin expression in obese individuals.
Why this rating
The paper cites studies but notes that the exact mechanisms are complex and not fully agreed upon.
Source
<p>Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications</p>
Yohannes Tsegyie Wondmkun · Diabetes Metabolic Syndrome and Obesity · 2020
DOI 10.2147/dmso.s275898
narrative_reviewCited 680×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity triggers insulin resistance and type 2 diabetes through chronic low-grade inflammation driven by visceral adipose tissue expansion, which releases pro-inflammatory cytokines (TNF-α, IL-6) and activates Toll-like receptors (TLR4) to interfere with insulin signaling.Good
- Mitochondrial dysfunction and ectopic lipid accumulation (triglycerides in muscle and liver) contribute to insulin resistance by reducing oxidative activity and ATP synthesis, leading to intramyocellular fat accumulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →